Clinical Study on the Integrated Chinese and Western Medicine Treatment of Immunodeficient Patients Infected with the Novel Coronavirus

² Reproduction and Development Research Institute of Fudan University, Shanghai Institute of Planned Parenthood Research, NHC Key Laboratory of Contraceptives and Devices, Shanghai 200032, China

³ Gaoling District Hospital, Xi’an 710200, Shaanxi, China

AMCMR 2026 , 2(3), 75–79; https://doi.org/10.61369/AMCMR.202603010

© 2026 by the Author. Licensee Art and Technology, USA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Abstract

During the severe outbreak of novel coronavirus pneumonia (COVID-19) across China, the epidemic spread to the Yan’an region, resulting in local cases. This report describes an immunodeficient patient infected with the novel coronavirus who was successfully cured through active integrated Chinese and Western medicine treatment at our hospital. We present the outcomes of this combined therapy to better contribute to the current fight against the epidemic and to further explore the underlying mechanisms of integrated Chinese and Western medicine, which remains highly significant for managing current post-infection sequelae.

Keywords

Immunodeficiency

Coronavirus

Integrated medicine

Funding

Yan’an University Prevention and treatment of New Coronal pneumonia Emergency Research Fund Project (Project No.: YDKYYJ03, YDKYYJ01); Shanxi Province 2020 traditional Chinese Medicine Prevention and treatment of New Coronal pneumonia Scientific Research Emergency Project (Project No.: 2020-YJ007, 2020-YJ005)

References

[1] Huang C, Wang Y, Li X, et al., 2020, Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China. Lancet, 395(10223): 497–506.

[2] Chen S, Cui N, Li Z, 2020, Clinical Research Progress of Xuebijing Injection in the Treatment of Sepsis. Chinese Journal of Integrative Medicine in Intensive and Critical Care, 27(1): 1–4.

[3] National Health Commission of the People’s Republic of China, 2020, Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 5).

[4] Qin C, Zhou L, Hu Z, et al., 2020, Dysregulation of Immune Response in Patients With COVID-19 in Wuhan, China. Clinical Infectious Diseases, 71(15): 762–768.

[5] Chinese Society of Infectious Diseases, Chinese Medical Association, 2020, Expert Consensus on Anti-Infective Treatment for Immunodeficient Patients (2020 Edition). Chinese Journal of Infectious Diseases, 38(4): 201–212.

[6] Li L, Zhang Z, Liu Y, 2015, Effect of Volatile Oil of Atractylodes lancea on Phagocytic Function of Peritoneal Macrophages in Mice. Chinese Journal of Experimental Traditional Medical Formulae, 21(8): 142–145.

[7] Wang L, Hou F, Zhao X, 2018, Research Progress on Anti-Inflammatory and Immunomodulatory Effects of Magnolol. China Journal of Chinese Materia Medica, 43(12): 2450–2455.

Previous article in this issue

Next article in this issue